ML385: Selective NRF2 Inhibitor for Cancer & Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a highly selective small molecule inhibitor of the transcription factor NRF2, with an IC50 of 1.9 μM in A549 cell models (APExBIO). ML385 effectively downregulates NRF2-dependent gene expression, impacting cellular antioxidant and detoxification pathways in a dose- and time-dependent manner (Wang et al., 2024). In vivo, ML385 reduces tumor growth and enhances the efficacy of chemotherapeutic agents such as carboplatin in non-small cell lung cancer (NSCLC) mouse models. ML385 is also validated as a tool to dissect ferroptosis and inflammation pathways, with proven selectivity and reproducibility in both cancer and neurodegeneration research. As a research-use-only compound supplied by APExBIO, ML385 enables advanced mechanistic studies in NRF2 signaling and therapeutic resistance (see comparison).

Biological Rationale

NRF2 (nuclear factor erythroid 2-related factor 2) is a master transcription factor that regulates cellular antioxidant response elements (AREs). Under physiological conditions, NRF2 controls genes involved in detoxification, antioxidant defense, and multidrug transporter expression (Wang et al., 2024). In many cancers, including NSCLC, NRF2 is constitutively activated, leading to increased resistance to chemotherapy and oxidative stress. NRF2 signaling is also implicated in ferroptosis regulation, inflammation, and metabolic reprogramming. Selective inhibition of NRF2, as achieved by ML385, allows researchers to dissect these pathways and study their contributions to disease progression and therapeutic resistance (see mechanistic review).

Mechanism of Action of ML385

ML385 is a small molecule that selectively binds to NRF2 and disrupts its ability to bind DNA, specifically ARE sequences. This inhibition prevents NRF2 from activating downstream genes involved in antioxidant response and detoxification. ML385 demonstrates high selectivity for NRF2 over other transcription factors at concentrations below 10 μM. In cellular assays, ML385 downregulates expression of classic NRF2 targets such as HO-1, GPX4, and NQO1 in a dose- and time-dependent manner. In vivo, ML385 reduces NRF2 signaling in tumor tissues and sensitizes cancer cells to chemotherapy-induced oxidative stress (Wang et al., 2024).

Evidence & Benchmarks

• ML385 inhibits NRF2 transcriptional activity with an IC50 of 1.9 μM in A549 NSCLC cells (APExBIO).
• ML385 treatment in NSCLC mouse models reduces tumor growth and metastatic potential, especially when combined with carboplatin (APExBIO).
• In T2DM mouse models, ML385 abolishes artemisinin-mediated neuroprotection by preventing NRF2 activation and increasing neuronal ferroptosis (Wang et al., 2024).
• ML385 downregulates NRF2-dependent genes (HO-1, GPX4) and increases oxidative stress markers (ROS, MDA, Fe²⁺) in neuronal tissue (Wang et al., 2024).
• ML385 is insoluble in water/ethanol but soluble at ≥13.33 mg/mL in DMSO; purity is ≥98% and recommended storage is at -20°C (APExBIO).
• ML385 is validated for use in oxidative stress, ferroptosis, inflammation, and cancer biology research (workflow guide).

Applications, Limits & Misconceptions

ML385 is primarily used in preclinical research to probe NRF2-dependent processes in cancer, neurodegeneration, and metabolic disease. It is especially valued for exploring mechanisms of therapeutic resistance and oxidative stress modulation. ML385 has shown efficacy in combination therapy studies, notably with carboplatin in NSCLC models, enhancing cytotoxicity by suppressing the NRF2-mediated defense response.

While ML385 is robust in vitro and in vivo, it is not intended for clinical or diagnostic use. ML385’s insolubility in water and ethanol requires careful handling during assay development. It is not a broad-spectrum antioxidant inhibitor, but rather, is highly selective for NRF2-dependent signaling. Long-term storage of solutions is not recommended due to potential compound degradation. Researchers should confirm NRF2-dependence in their models, as ML385 may have limited effects in NRF2-independent contexts (see performance review).

Common Pitfalls or Misconceptions

• ML385 is not suitable for diagnostic or therapeutic human use; it is for research only.
• It does not inhibit other oxidative stress pathways unrelated to NRF2 (e.g., SOD, catalase directly).
• ML385 is ineffective if NRF2 is not functionally expressed or activated in the experimental model.
• Water or ethanol-based solvents cannot dissolve ML385; only DMSO is recommended.
• Long-term storage of ML385 solutions (vs. solid/frozen) leads to decreased potency.

Workflow Integration & Parameters

ML385 is supplied by APExBIO as a solid with ≥98% purity and a molecular weight of 511.59 g/mol. Recommended stock solution: dissolve at ≥13.33 mg/mL in DMSO. Store at -20°C, protected from light and moisture. For cell-based assays, typical working concentrations range from 0.5–10 μM, with timepoints of 2–48 hours depending on readout. For in vivo studies, ML385 is administered as per published protocols (e.g., via i.p. injection in mouse models). Always confirm NRF2 pathway activation status before use. For detailed workflow guidance and troubleshooting, see the ML385 workflow guide, which provides protocol optimization and troubleshooting strategies distinct from this product-focused dossier.

For benchmarking against other NRF2 inhibitors and translational perspectives, the strategic NRF2 pathway inhibition article offers a mechanistic and translational landscape, while this page focuses on ML385’s product-specific data and practical integration.

Conclusion & Outlook

ML385, as supplied by APExBIO, remains a leading selective NRF2 inhibitor for dissecting NRF2 signaling, oxidative stress, and therapeutic resistance mechanisms in cancer and neurodegeneration research. Its robust selectivity and reproducibility have been validated across in vitro and in vivo models, supporting its ongoing use in mechanistic and translational studies. Continued benchmarking and workflow optimization will further enhance ML385’s utility in preclinical research, enabling the next generation of studies on antioxidant response pathways and resistance mechanisms. For detailed product information and ordering, refer to the official ML385 product page.